BridgeMD
Effect of infLuenza vaccInation after Myocardial INfArction on cardiac inflammaTory responsE - a randomized, double-blind, placebo-controlled, trial (ELIMINATE trial)
EU CTIS ID: 2023-505361-86-00
What this study is testing
The primary objective is to compare influenza vaccination and placebo in reducing post myocardial infarction coronary inflammation as measured by CCTA.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with a diagnosis of non-ST-segment elevation myocardial infarction
- A finalized coronary PCI
- Male or non-fertile female subjects ≥18 years (Females without childbearing potential, postmenopausal women and women with a history of hysterectomy or other medical conditions that preclude pregnancy)
- Written informed consent
- A CCTA scan can be scheduled within 7 days after PCI
You likely can't join if
- Has received influenza vaccination within 6 months
- Previous randomization in the ELIMINATE trial
- Any non-cardiovascular condition, e.g. malignancy, with a life expectancy of less than 1 year based on the investigator´s clinical judgement.
- Contraindication to coronary CT angiography (e.g., inability to lie flat, contraindication to glyceryl trinitrate, previous contrast allergy or contrast-induced nephropathy, severe renal impairment [eGFR <30 mL/min/1.73 m2])
- Atrial fibrillation
- Uncontrolled chronic inflammatory disease
See the full eligibility criteria
- Patients with a diagnosis of non-ST-segment elevation myocardial infarction
- A finalized coronary PCI
- Male or non-fertile female subjects ≥18 years (Females without childbearing potential, postmenopausal women and women with a history of hysterectomy or other medical conditions that preclude pregnancy)
- Written informed consent
- A CCTA scan can be scheduled within 7 days after PCI
- Has received influenza vaccination within 6 months
- Previous randomization in the ELIMINATE trial
- Any non-cardiovascular condition, e.g. malignancy, with a life expectancy of less than 1 year based on the investigator´s clinical judgement.
- Contraindication to coronary CT angiography (e.g., inability to lie flat, contraindication to glyceryl trinitrate, previous contrast allergy or contrast-induced nephropathy, severe renal impairment [eGFR <30 mL/min/1.73 m2])
- Atrial fibrillation
- Uncontrolled chronic inflammatory disease
- Unable to comply with protocol requirements
- Other vaccination planned within 8 weeks (including covid-19 booster doses)
- Severe allergy to eggs or previous allergic reaction to influenza vaccine
- Cardiac surgery or staged PCI planned within 8 weeks
- Coronary stent involving the proximal RCA
- Suspicion of febrile illness or acute, ongoing infection
- Hypersensitivity to the active substances or ingredients of Vaxigrip or against any residues, such as eggs (ovalbumin or chicken proteins), neomycin, formaldehyde and octoxinol
- Subjects with endogenic or iatrogenic immunosuppression that may result in reduced immunization response
- Inability to provide informed consent
The study team makes the final eligibility decision.
Where it's taking place
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.